Focal Epilepsy Clinical Trials and Treatments

Focal epilepsy occurs when abnormal electrical activity repeatedly starts in a specific region of the brain. Unlike generalized epilepsy, which involves both brain hemispheres from the start, focal seizures begin in one area and may or may not spread. The seizures are classified as focal aware (consciousness preserved) or focal impaired awareness (consciousness affected), and can sometimes evolve into bilateral tonic-clonic seizures.

The most common symptoms of Focal Epilepsy include Auras or unusual sensations before seizures (déjà vu, rising stomach feeling, strange smells), Staring spells with impaired awareness lasting 30 seconds to 2 minutes, Involuntary repetitive movements like lip smacking, hand rubbing, or picking at clothes, Confusion and disorientation after seizures, Memory difficulties, especially with temporal lobe involvement, among others. Up to about 61% of people with epilepsy have focal seizures; about 2.9 million U.S. adults and 456,000 children have active epilepsy. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Focal Epilepsy from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Drug-resistant focal epilepsy represents one of the most active areas of clinical trial development. For patients whose seizures don't respond to standard medications, Biohaven's opakalim (BHV-7000), a Kv7 ion channel activator, is in Phase 2/3 trials; on September 4, 2026 the FDA placed a partial clinical hold that pauses new enrollment while patients already in the studies keep dosing, and RISE 3 results are still expected in the second half of 2026.

Yes. As of October 21, 2026, 21 FDA-approved medicines have a current label that names Focal Epilepsy: Briviact (brivaracetam), first approved in 2016; Fycompa (perampanel), first approved in 2012; Keppra (levetiracetam), first approved in 1999; Lamictal (lamotrigine), first approved in 1994; Vimpat (lacosamide), first approved in 2008; Xcopri (cenobamate), first approved in 2019; Afinitor Disperz (everolimus); Aptiom (eslicarbazepine acetate); Depakote (divalproex sodium / valproic acid / valproate sodium); Dilantin (phenytoin); Felbatol (felbamate); Gabitril (tiagabine hydrochloride); Lyrica (pregabalin); Mysoline (primidone); Neurontin (gabapentin); Sabril (vigabatrin); Tegretol (carbamazepine); Topamax (topiramate); Tranxene T-Tab (clorazepate dipotassium); Trileptal (oxcarbazepine); and Zonegran (zonisamide). Corticosteroids and immune globulins count once each.

The exact cause of Focal Epilepsy is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. Most focal epilepsy is structural, acquired or of unknown cause; a minority of familial focal epilepsies are monogenic (DEPDC5, NPRL2, NPRL3), so gene testing is considered mainly when there is a family history or early onset. Up to about 61% of people with epilepsy have focal seizures; about 2.9 million U.S. adults and 456,000 children have active epilepsy. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Focal Epilepsy. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. Most focal epilepsy is structural, acquired or of unknown cause; a minority of familial focal epilepsies are monogenic (DEPDC5, NPRL2, NPRL3), so gene testing is considered mainly when there is a family history or early onset.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Focal Epilepsy clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Focal Epilepsy clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.